Item 1(a).
Name of Issuer
Kura Oncology, Inc. (the "Issuer").
Item 1(b).
Address of Issuer's Principal Executive Offices
11119 N. Torrey Pines Road, Suite 125, La Jolla, CA 92037.
Item 2(a).
Name of Person Filing
ARCH Venture Fund VIII, L.P. ("ARCH Venture Fund VIII"); ARCH Venture Partners VIII, L.P. ("AVP VIII LP"); ARCH Venture Partners VIII, LLC ("AVP VIII LLC") (collectively, the "Reporting Entities" and individually, each a "Reporting Entity"); and Keith Crandell ("Crandell"), Robert Nelsen ("Nelsen") and Clinton Bybee ("Bybee") (collectively, the "Managing Directors" and individually, each a "Managing Director"). The Reporting Entities and the Managing Directors collectively are referred to as the "Reporting Persons".
Item 2(b).
Address of Principal Business Office or, if none, Residence
8755 W. Higgins Avenue, Suite 1025, Chicago, IL 60631
Item 2(c).
Citizenship
ARCH Venture Fund VIII and AVP VIII LP are limited partnerships organized under the laws of the State of Delaware. AVP VIII LLC is a limited liability company organized under the laws of the State of Delaware. Each Managing Director is a US citizen.
Item 2(d).
Title of Class of Securities
Common stock, par value $0.0001 per share.
Item 2(e).
CUSIP Number
50127T 109
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
Not Applicable.
Item 4.
Ownership
(a)
|
Amount beneficially owned:
ARCH Venture Fund VIII is the record owner of 1,888,687 shares of Common Stock (the "Record Shares") as of December 31, 2016. AVP VIII LP, as the sole general partner of ARCH Venture Fund VIII, may be deemed to beneficially own the Record Shares. AVP VIII LLC, as the sole general partner of AVP VIII LP, may be deemed to beneficially own the Record Shares. As managing directors of AVP VIII LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the Record Shares.
|
|
|
(b)
|
Percent of class:
In the aggregate, the Reporting Persons beneficially own 8.8% of the outstanding shares of common stock of the Issuer, based upon 21,367,747 shares of common stock outstanding as of November 2, 2016 as reported on the Issuer's Form 10-Q as filed with the Securities and Exchange Commission on November 7, 2016.
|
CUSIP No. 50127T 109
|
13G
|
Page 9 of 12 Pages
|
(c)
|
Number of shares as to which such person has:
|
|
(i)
|
Sole power to vote or to direct the vote:
0 shares for each Reporting Person
|
|
|
|
|
(ii)
|
Shared power to vote or to direct the vote:
Each of the Reporting Persons: 1,888,687
|
|
|
|
|
(iii)
|
Sole power to dispose or to direct the disposition:
0 shares for each Reporting Person
|
|
|
|
|
(iv)
|
Shared power to dispose or to direct the disposition:
Each of the Reporting Persons 1,888,687
|
|
|
|
Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.
Item 5.
Ownership of Five Percent or Less of a Class
Not Applicable.
Item 6.
Ownership of More than Five Percent on Behalf of Another Person
Not Applicable.
Item 7.
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
|
Not Applicable.
Item 8.
Identification and Classification of Members of the Group
Not Applicable.
Item 9.
Notice of Dissolution of Group
Not Applicable.
Item 10.
Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
CUSIP No. 50127T 109
|
13G
|
Page 10 of 12 Pages
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 13, 2017
ARCH VENTURE FUND VIII, L.P.
By:
ARCH Venture Partners VIII, L.P.
its General Partner
By:
ARCH Venture Partners VIII, LLC
its General Partner
By:
*
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, L.P.
By:
ARCH Venture Partners VIII, LLC
its General Partner
By:
*
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, LLC
By:
*
Keith Crandell
Managing Director
*
Keith Crandell
* By:
/s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
This Amendment No. 2 to Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as
Exhibit 2
and incorporated herein by reference.
CUSIP No. 50127T 109
|
13G
|
Page 11 of 12 Pages
|
EXHIBIT 1
AGREEMENT
Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Kura Oncology, Inc.
This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.
Dated: February 13, 2017
ARCH VENTURE FUND VIII, L.P.
By:
ARCH Venture Partners VIII, L.P.
its General Partner
By:
ARCH Venture Partners VIII, LLC
its General Partner
By:
*
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, L.P.
By:
ARCH Venture Partners VIII, LLC
its General Partner
By:
*
Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, LLC
By:
*
Keith Crandell
Managing Director
*
Keith Crandell
* By:
/s/ Mark McDonnell
Mark McDonnell as
Attorney-in-Fact
This Agreement was executed by Mark McDonnell pursuant to Powers of Attorney attached hereto as
Exhibit 2
and incorporated herein by reference.
CUSIP No. 50127T 109
|
13G
|
Page 12 of 12 Pages
|
EXHIBIT 2
POWERS OF ATTORNEY
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark McDonnell his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirect general partner, member, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and any and all regulations promulgated thereunder, and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his substitutes, may lawfully do or cause to be done by virtue hereof. This Power of Attorney shall remain in full force and effect with respect to each undersigned person unless and until six months after such person is both no longer a Managing Director of ARCH Venture Partners and no longer serving on the board of directors of any portfolio company of any ARCH Venture Partners fund.
IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 9
th
day of March, 2015.
ARCH VENTURE FUND VIII, L.P.
By:
ARCH Venture Partners VIII, L.P.
its General Partner
By:
ARCH Venture Partners VIII, LLC.
its General Partner
By:
/s/ Keith Crandel
l
Managing Director
ARCH VENTURE PARTNERS VIII, L.P.
By:
ARCH Venture Partners VIII, LLC
its General Partner
By:
/s/ Keith Crandell
Managing Director
ARCH VENTURE PARTNERS VIII, LLC
By:
/s/ Keith Crandell
Managing Director
/s/ Keith Crandell
Keith Crandell
/s/ Robert Nelsen
Robert Nelsen
/s/ Clinton Bybee
Clinton Bybee
/s/ Kristina Burow
Kristina Burow
/s/ Paul Thurk
Paul Thurk